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Abstract 34	  
 35	  
Urinary tract infections (UTIs) are one of the most common infectious diseases of humans, with 36	  
approximately 150 million cases estimated to occur globally every year. UTIs usually start as a 37	  
bladder infection (cystitis), but can develop into acute kidney infection (pyelonephritis) and even 38	  
infection of the bloodstream (urosepsis). The high frequency of UTIs in community and nosocomial 39	  
settings places an enormous burden on healthcare systems worldwide. Multiple different pathogens 40	  
cause UTI, with uropathogenic E. coli (UPEC) the most common etiological agent. UTIs caused by 41	  
these pathogens are increasingly associated with antibiotic resistance, thus severely reducing 42	  
treatment options and significantly increasing UTI-associated morbidity and mortality. In this 43	  
review we present an overview of the recent advances in vaccine research targeted towards the 44	  
prevention of UPEC-mediated UTI. In the context of multidrug resistance, we conclude that 45	  
vaccination represents a viable approach for the prevention of chronic and recurrent UTI. 46	  
 47	  
 48	  
 49	  
 50	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Clinical importance and impact of urinary tract infections (UTIs) 52	  
 53	  
UTIs are one of the most common infections of humans. They affect approximately 12% of women 54	  
and 3% of men in the United States every year [1] and also represent a major cause of 55	  
hospitalization [2]. UTIs present as uncomplicated or complicated infections of the bladder 56	  
(cystitis) or kidney (pyelonephritis) and are frequently observed in both nosocomial and community 57	  
settings. Acute cystitis and pyelonephritis episodes in healthy premenopausal, non-pregnant women 58	  
with no evidence of an abnormal urinary tract are usually classified and treated as uncomplicated. 59	  
Complicated UTIs generally affect patients with structural or functional abnormalities that may 60	  
compromise therapy and lead to urosepsis. UTIs are also categorized as isolated, unresolved or 61	  
recurrent (due to reinfection or relapse) and, altogether, these classifications inform the selection 62	  
and duration of antibiotics used in treatment [3, 4]. Another form of UTI, termed asymptomatic 63	  
bacteriuria (ABU), represents an asymptomatic carrier state in which patients may carry >105 64	  
CFU/ml of a single organism for years without provoking a host response. ABU is generally left 65	  
untreated unless there are additional risk factors, such as during pregnancy [5]. 66	  
 67	  
Cystitis, the most common infection of the urinary tract, generally resolves quickly in response to 68	  
antibiotic treatment (3.32 ± 2.54 days). The mean duration of symptoms is increased when incorrect 69	  
antibiotics are administered due to infection with drug-resistant strains (4.73 ± 2.91 days) or where 70	  
treatment is delayed (4.94 ± 3.82 days) [6]. Overall, the global burden of UTI is responsible for 71	  
huge health care costs throughout the world. Indeed, in 1995, it was estimated that 11.3 million 72	  
women received treatment for a UTI in the United States, leading to an estimated direct cost of 1.6 73	  
billion dollars [7]. Community-acquired UTIs also represent approximately 0.7% of ambulatory 74	  
care visits, which in 2007 alone corresponded to 8.6 billion patient episodes in the USA [8].  75	  
 76	  
The total burden of UTI is significantly higher in women than men. This is strongly linked to 77	  
anatomical differences in the urinary tract; women have a shorter distance between the bladder and 78	  
the urethra, and the urethral opening of women is proximate to vaginal cavity and rectum, thus 79	  
increasing the opportunity for infection [9]. It is estimated that one in three women experience a 80	  
UTI by the age of 24 years and at least 40-50% of women experience a UTI in their lifetime [5]. 81	  
Uncomplicated UTIs in women are often associated with sexual activity, with the peak incidence of 82	  
disease occurring between 18-39 years of age [10]. UTIs are also a common infection in childhood, 83	  
affecting approximately 7-8% of girls and 2% of boys. It is estimated that one out of ten girls and 84	  
one out of thirty boys will present with a UTI by the age of 16 years [11].  85	  
 86	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Nosocomial UTIs also contribute a significant economic burden to hospitals and health care 87	  
facilities. The incidence of nosocomial UTI in catheterized inpatients is estimated to be 7.3% [12]. 88	  
In the UK, it is estimated that acquisition of a UTI following surgery results in a mean of 3.6 89	  
additional hospital days per infected patient. This equates to an approximate cost of one thousand 90	  
British pounds per patient, and constitutes a major economic impact given that approximately 1.6% 91	  
of inpatients are estimated to acquire a UTI [12].  92	  
 93	  
Urosepsis is a severe complication of UTI that results when bacteria cross into the bloodstream and 94	  
can be life-threatening. Urosepsis is estimated to develop in 3.6-12.6% of UTI cases [13, 14], with a 95	  
mortality rate of up to 12.7% [13]. 96	  
 97	  
Causative agents and antibiotic resistance 98	  
 99	  
Uropathogenic Escherichia coli (UPEC) is the most common causative agent of UTI, and is 100	  
responsible for 75-95% of all cases of uncomplicated cystitis and pyelonephritis [3]. Other common 101	  
Gram-negative and Gram-positive bacterial pathogens that cause UTI include Pseudomonas 102	  
aeruginosa, Klebsiella pneumoniae, Klebsiella oxytoca, Proteus mirabilis, Proteus vulgaris, 103	  
Enterobacter cloacae, Enterobacter aerogenes, Morganella morganii, Acinetobacter baumannii, 104	  
Staphylococcus saprophyticus and Enterococcus species [15]. The range of pathogens that cause 105	  
nosocomial UTI is generally more diverse [16]. 106	  
 107	  
UTIs are the second most common reason for antibiotic prescription, preceded only by otitis media 108	  
[9]. Community-acquired uncomplicated UTIs are generally treated empirically, since UPEC causes 109	  
the majority of infections and short-course therapies are usually completed before laboratory 110	  
analysis is available. This strategy has likely contributed to the increased incidence of extended-111	  
spectrum β-lactamase (ESBL)-producing strains worldwide, as well as to episodes of subclinical 112	  
persistence and recurrence following treatment [17, 18]. The emergence and dissemination of 113	  
multidrug-resistant clones such as E. coli sequence type 131 (E. coli ST131), as well as other 114	  
sequence types including ST69, ST73 and ST95, has significantly reduced treatment options and 115	  
threatens to make UTI a major threat to public health worldwide [19, 20, 21, 22, 23, 24, 25, 26, 27]. 116	  
Indeed, several large surveillance studies performed over the last two decades have demonstrated 117	  
that in some regions across the globe, 20-50% of all UPEC strains are resistant to commonly 118	  
prescribed antibiotics such as trimethoprim-sulfamethoxazole, fluoroquinolones and β-lactams [9]. 119	  
Recent studies also indicate that ESBL-producing strains are associated with 6.6% of community-120	  
acquired and 26.8% of nosocomial bacteremia caused by E. coli; and are associated with 121	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significantly higher morbidity (up to 60.8%) than non-ESBL-producing E. coli strains (23.7%) [28]. 122	  
In a recent retrospective study, human and animal E. coli isolates collected from 1950 and 2002 123	  
were assessed for historical changes in their resistance profile to 15 antibiotics. Multidrug resistance 124	  
(i.e. resistance to at least 3 drug classes) increased from 7.2% during the 1950s to 63.6% during the 125	  
2000s [29]. These alarming trends have led to an increase in the use of second- and third-line 126	  
therapies, further promoting the emergence of multidrug-resistant strains and highlighting the need 127	  
for alternative treatment and prevention approaches. 128	  
 129	  
Vaccination approaches to prevent UTI 130	  
 131	  
Infection of the urinary tract by UPEC is associated with the expression of multiple virulence 132	  
factors, including fimbrial adhesins, autotransporter proteins, toxins, siderophores, flagella and 133	  
polysaccharides that comprise specific capsule and O antigen surface structures [30] (Figure 1). It is 134	  
not surprising, therefore, that most vaccine efforts to-date have involved targeting these UPEC 135	  
surface or secreted factors, either as single or multi-component formulations. 136	  
 137	  
Preventing adhesion to the urinary tract 138	  
 139	  
Adherence represents a fundamental initial step in colonization of the urinary tract and is generally 140	  
mediated by fimbrial adhesins, which enable pathogens to bind to the uroepithelium, to avoid 141	  
clearance through the washing effect of urine and to mediate intimate interactions with host 142	  
epithelial cells. Adhesins are structurally variable and mediate specific attachment to different 143	  
receptors on epithelial cells in a lock-and-key fashion. Type 1 fimbriae are directly associated with 144	  
UPEC infection and persistence in the mouse urinary tract [31, 32] by virtue of their ability to 145	  
mediate binding to α-D-mannosylated proteins such as uroplakins Ia and Ib, two major 146	  
glycoproteins present on the apical surface of superficial bladder epithelial cells [33]. Type 1 147	  
fimbriae-facilitated adhesion is mediated specifically by FimH, a minor subunit localized at the tip 148	  
of the fimbrial structure [34, 35]. The use of FimH (truncated or in complex with the periplasmic 149	  
chaperone FimC) as a vaccine candidate has been shown to inhibit the binding of UPEC to human 150	  
epithelial bladder cells in vitro [36]. Moreover, systemic immunization with FimH (in combination 151	  
with the FimC chaperone protein) promoted a strong and long-lasting immune response that led to a 152	  
>99% reduction in bladder colonization in a murine model of cystitis, and prevention of kidney 153	  
infection over a 7-day period. Immunization with FimH also correlated with a high titer of anti-154	  
FimH IgG antibodies in the urine of mice [36]. Further studies using a primate model of UTI 155	  
revealed that immunization with FimH (in complex with FimC) led to high vaginal anti-FimH titers 156	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and resulted in significant protection from UTI following UPEC challenge [37]. A vaccine 157	  
containing the FimH protein fused to the FliC major flagellin subunit (FimH-FliC) has also been 158	  
recently described [38]. Mice immunized with the FimH-FliC protein induced a significant humoral 159	  
and cellular immune response, and were protected from UPEC infection of the bladder and kidney 160	  
in a mouse UTI model [38, 39]. 161	  
 162	  
P fimbriae, another adhesive component associated with UPEC infection of the urinary tract, 163	  
mediate adhesion to α-D-galactopyranosyl-(1-4)-β-D-galactopyranoside receptor epitopes in the 164	  
globoseries of glycolipids present on vaginal and kidney epithelial cells via the tip-located PapG 165	  
adhesin [40, 41, 42, 43]. Previous studies have demonstrated protection against renal colonization in 166	  
murine models of infection [44, 45]. PapG, in complex with the periplasmic chaperone PapD, was 167	  
used to vaccinate cynomolgus monkeys to evaluate protection against pyelonephritis. Vaccinated 168	  
monkeys possessed increased anti-PapDG IgG titers and were protected from pyelonephritis 169	  
following challenge. However, despite histological evidence for reduced inflammation, no 170	  
difference was observed in the number of bacteria recovered from the urine of vaccinated and 171	  
control groups [46]. It is possible these observations could be explained by the expression of other 172	  
adhesins, such as type 1 fimbriae, that also mediate binding to uroepithelial cells [46]. 173	  
 174	  
UPEC express a number of additional fimbrial adhesins that are associated with UTI, including 175	  
Afa/Dr fimbriae [47], F1C fimbriae [48], S fimbriae [49], and type 3 fimbriae [50]. Among these 176	  
adhesins, only Afa/Dr fimbriae, which mediate binding to decay-accelerating factor, type IV 177	  
collagen and carcinoembryonic antigen-related cell adhesion molecules in the upper urinary tract 178	  
[51], have been examined as a putative vaccine target. Vaccination with Afa/Dr fimbriae led to a 179	  
reduction in UPEC adherence to bladder cells in a UTI mouse infection model [52]. 180	  
 181	  
Several other UPEC virulence factors associated with adherence have been examined with respect 182	  
to their potential role as vaccine targets. The UPEC trimeric autotransporter UpaG was identified by 183	  
reverse vaccinology as a potentially protective antigen against extra-intestinal pathogenic E. coli 184	  
[53]. UpaG promotes cell aggregation, biofilm formation, and binding to human bladder epithelial 185	  
cells as well as to the extracellular matrix proteins fibronectin and laminin [54]. Using the prototype 186	  
pyelonephritis-associated UPEC strain CFT073 in a murine sepsis model, immunization with UpaG 187	  
(c4424) resulted in a 33% protection rate following active immunization and a 66% protection rate 188	  
following passive immunization [53]. Intranasal vaccination with FdeC (ECOK1_0290), an outer 189	  
membrane protein that mediates adhesion to human bladder and urethral epithelial cells, has also 190	  
been examined. Vaccination of mice with FdeC led to a 1.5-2.5 log reduction in UPEC kidney 191	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colonization using a UTI model, thus demonstrating significant protection against pyelonephritis 192	  
[55]. FdeC has also been identified as a protective antigen in a murine model of sepsis [56].  193	  
 194	  
Preventing damage to uroepithelial cells 195	  
 196	  
An important feature of UPEC pathogenesis is the ability to scavenge nutrients from the urinary 197	  
tract. UPEC can secrete several toxins that damage uroepithelial cells and promote the release of 198	  
nutrients into the urine. Alpha hemolysin (HlyA) is a pore-forming cytotoxin secreted by some 199	  
UPEC strains [57]. Hemolysin has been purified from UPEC culture supernatants and tested as a 200	  
vaccine candidate in a murine model of pyelonephritis. Mice immunized with denatured hemolysin 201	  
showed less renal injury compared to control groups, however no significant effect was observed on 202	  
kidney colonization [58]. In a separate study, systemic immunization with recombinant HlyA led to 203	  
a protection rate of 86% in a murine model of sepsis [56]. Another UPEC toxin, the vacuolating 204	  
autotransporter cytotoxin (Vat), is a serine protease also secreted by avian pathogenic E. coli 205	  
(APEC) [59]. The vat gene is located on a pathogenicity island, which likely accounts for its high 206	  
prevalence in both UPEC and APEC strains. In a murine model of sepsis, Vat (c0393) led to a 207	  
protection rate of 32% and 78% by active and passive immunization, respectively [53]. 208	  
 209	  
Preventing the scavenging of nutrients from urine 210	  
 211	  
The ability to capture nutrients in the resource-limited urinary tract is an essential feature of 212	  
pathogens that colonize this niche and cause UTI. Most UPEC strains possess a range of 213	  
mechanisms to effectively capture iron. This includes a number of siderophores, namely 214	  
enterobactin, salmochelin, aerobactin and yersiniabactin [60, 61, 62, 63]. IroN, a receptor for 215	  
salmochelin, is associated with UPEC colonization of the urinary tract [63, 64, 65]. Subcutaneous 216	  
immunization with denatured IroN led to a specific IgG response in serum and protection against 217	  
renal infection in a murine model of ascending UTI, however protection against bladder infection 218	  
and production of mucosal IgA was not observed [66]. IroN has also been tested as a vaccine 219	  
candidate in a murine model of sepsis, and led to a protection rate of 82% by active immunization 220	  
and 79% by passive immunization following UPEC challenge [53].  221	  
 222	  
More recent work on UPEC iron receptors has demonstrated they hold significant promise as 223	  
potential vaccine candidates [53, 67]. Intranasal immunization with the iron receptor proteins IreA, 224	  
Hma and IutA, conjugated to cholerae toxin, was able to elicit a specific systemic and mucosal 225	  
immune response capable of conferring protection in a murine model of UTI. Vaccination with 226	  
	   8 
Hma, a haem receptor required for kidney colonization [68], protected mice against colonization of 227	  
the kidney, while vaccination with IreA, a less-well characterised iron receptor required for bladder 228	  
colonization [69], showed significant protection against bladder infection, even against 229	  
heterologous UPEC strains [67]. IutA, a receptor for aerobactin, was also able to confer significant 230	  
protection against UPEC infection of the mouse bladder and kidney [67]. In a murine model of 231	  
sepsis, FyuA, the yersiniabactin receptor, led to a protection rate of 53% by active immunization 232	  
and 72% by passive immunization [53]. Intranasal immunization with FyuA also resulted in a 29-233	  
fold decrease in kidney colonization in a murine model of UTI compared to control groups [70]. 234	  
Finally, vaccination of mice with FitA (ECOK1_3457), a putative iron receptor [71], resulted in a 235	  
protection efficacy of 25% in a sepsis model [56]. 236	  
 237	  
Iron receptors are integral outer membrane proteins that contain surface loops exposed to the 238	  
external milieu and interact with siderophore-iron complexes. The external loops of IroN and IutA 239	  
have been synthesized as synthetic linear peptides and tested for their ability to protect mice from 240	  
UTI. In these studies, a 2-log reduction in colonization of the kidney was observed after UPEC 241	  
challenge [67]. Furthermore, when administered as a multi-epitope vaccine, synthetic vaccine 242	  
proteins with concatenated epitopes Vol1 (combination of IutA, IhaA, FyuA and Usp epitopes) and 243	  
Vol2 (IreA, ChuA and IroN epitopes) resulted in a significant 2-log reduction in bacterial load in 244	  
the spleen and liver using a murine model of peritonitis infection [72].  245	  
 246	  
Preventing escape from immune cells 247	  
 248	  
Protection against innate host defenses is strongly associated with UPEC pathogenesis of the 249	  
urinary tract. Several specific O antigen and capsular polysaccharide types are highly prevalent 250	  
among UPEC strains, and confer resistance against antibacterial peptides, phagocytosis and 251	  
complement mediated killing [73]. The use of chemically inactivated UPEC strains to generate 252	  
specific antibodies against O and K antigens was one of the first strategies employed to prevent UTI 253	  
[74, 75]. Targeting of UPEC surface polysaccharides has been attempted using both active 254	  
(intraperitoneal and intravesical) and passive (urine transfer) immunization in a rat ascending UTI 255	  
model, showing increased protection against homologous strains but a reduced impact on 256	  
heterologous strains [76]. 257	  
 258	  
Uro-Vaxom, a lyophilized lysate prepared from 18 UPEC strains and licensed for human 259	  
application (Galenica Group), has been tested in a double-blind randomized study of patients with 260	  
recurrent UTI from 52 centers and nine different countries [77]. Female patients aged 18-65 years 261	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with at least three documented episodes of UTI in the previous year were included in the 262	  
investigation. Capsules containing the treated UPEC lysates were administered daily during the first 263	  
three months, followed by no treatment during months 4-6, and then one capsule daily during the 264	  
first ten days of months seven to nine. In this trial, the treated group achieved a 14.7% reduction in 265	  
UTI episodes compared to control group. Interestingly, after month seven, the reduction increased 266	  
to 43%, possibly associated with the administration of booster doses. The vaccine significantly 267	  
impacted on the number of recurrent UTI episodes, which were reduced by 49% in the treated 268	  
group compared to placebo [77]. 269	  
 270	  
Urovac, another lyophilized vaccine formulation, contains heat-killed bacteria from ten 271	  
uropathogenic strains (six UPEC strains, K. pneumoniae, P. mirabilis, M. morganii and E. faecalis) 272	  
[78]. After several Phase II clinical studies using different schedules of immunization to determine 273	  
vaccine efficacy [79, 80, 81], Urovac was tested in a randomized, double-blind clinical trial using 274	  
women who had suffered at least three recurrent UTIs in the previous year. Patients were initially 275	  
immunized with three vaginal suppositories at weekly intervals followed by three additional 276	  
suppositories at monthly intervals. Overall, vaccination with Urovac significantly reduced recurrent 277	  
UTI over a six-month period (46% infection-free) compared to a placebo control group (16.7% 278	  
infection-free). Moreover, a major impact of vaccination with Urovac was observed in sexually 279	  
active women [82]. 280	  
 281	  
A live-attenuated vaccine against UTI has also been proposed using a rough mutant of the UPEC 282	  
strain NU14. This mutant strain stimulated a strong urothelial cytokine response and protection in 283	  
mice for up to 8 weeks against challenge by direct inoculation into the bladder. The same pattern of 284	  
protection was demonstrated for several other UPEC strains, demonstrating a reduction in bladder 285	  
colonization and cross-protection against different UPEC serotypes [83]. While used 286	  
prophylactically rather than directly as a vaccine, the ABU E. coli strain 83972 has also been shown 287	  
to reduce UPEC colonization in animal and human infection studies [84, 85, 86, 87, 88]. The 288	  
potential of killed whole-cell vaccines has also been examined through the generation of a 289	  
genetically engineered UPEC strain deficient in capsule and O-antigen synthesis. A formalin-killed 290	  
preparation of this strain administered intranasally into mice led to an increased humoral immune 291	  
response and increased opsonophagocytosis of UPEC following challenge [89]. 292	  
 293	  
Other antigens may also contribute to the ability of UPEC to avoid immune responses in the urinary 294	  
tract. For example, EsiB (c5321), a protein that interacts with secretory IgA and inhibits neutrophil 295	  
	   10 
chemotaxis as well as the respiratory burst [90], showed a protection efficacy of 33% in a murine 296	  
model of sepsis [56]. 297	  
 298	  
Hypothetical proteins as vaccine targets 299	  
 300	  
Some UPEC proteins have been shown to elicit a strong immune response and provide protection in 301	  
an infection model despite their lack of an assigned function. This includes SslE (ECOK1_3385), a 302	  
secreted and surface-exposed E. coli lipoprotein [56, 91] potentially associated with the degradation 303	  
of mucosal glycoproteins such as mucin [92]. Active immunization of mice with SslE resulted in a 304	  
protection efficacy of 82% in a murine model of sepsis. SslE is secreted by a type 2 secretion 305	  
system (T2SS), and active immunization of mice with a surface-exposed component of this T2SS 306	  
(ECOK1_3374) also resulted in protection from infection, albeit at a significantly lower level. 307	  
Protection following passive immunization with rabbit polyclonal antibodies against SslE using the 308	  
same model reached 100%, and cross-protection against heterologous UPEC strains was also 309	  
demonstrated [56]. 310	  
 311	  
Several additional uncharacterized proteins have been shown to confer protection against UPEC in 312	  
a mouse sepsis infection model. This includes the OmpA-like protein c3389 (38% protection by 313	  
active immunization, 100% protection by passive immunization) [53], c1275 (45% protection by 314	  
active immunization) and c0975 (24% protection by active immunization) [56]. 315	  
 316	  
Outlook and perspectives on vaccine development against UTI 317	  
 318	  
A vaccine aimed at the prevention of UTI would have a major impact on the quality of life for many 319	  
individuals who suffer from chronic and recurrent UTI. As UPEC represent the primary causative 320	  
agent of UTI, one could envisage that this pathogen would be the primary target of such a vaccine. 321	  
However, other common UTI pathogens should also be considered where feasible. The variation in 322	  
UPEC serotypes that cause UTI, together with the diversity of virulence factors that are expressed 323	  
by different UPEC strains, adds complexity to the design of an effective UTI vaccine. Ideally, one 324	  
would expect a UTI vaccine to be multi-component and have broad coverage that at a minimum 325	  
provides protection against all UPEC strain types. On the other hand, targeting a common 326	  
component of the commensal intestinal flora increases the challenge associated with such a vaccine, 327	  
as changes in the human microbiota may lead to other complications [93]. Considering the advances 328	  
in metagenomics [94] and the recent outcomes of the Human Microbiome Project [95, 96], a 329	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comparison of the gut microbiota between pre- and post-vaccinated individuals would finally 330	  
address the direct and indirect impact of a UTI vaccine on intestinal homeostasis. 331	  
 332	  
The use of multiple animal infection models in combination with a range of UPEC targets has 333	  
demonstrated the feasibility of a vaccine to prevent UTI in humans. Systemic and mucosal 334	  
immunization has also been shown to confer protection in the urinary tract, even though the 335	  
generation of long-lasting responses still needs to be demonstrated. So why is a broadly protective 336	  
UTI vaccine still not available? Our analysis of publicly available pipelines only identified three 337	  
vaccine companies that are directly investing in a vaccine against UTI (Table 1). The main reasons 338	  
for this may be a combination of marketing strategies and the target population for such a vaccine. 339	  
Despite the huge increase in multidrug resistant strains that cause UTI over the last decade and the 340	  
consequent economic burden associated with treatment failure (including extended therapy and 341	  
increased recovery time), UTIs can in most cases still be treated by an appropriate antibiotic 342	  
regimen. Therefore, despite the impact of a UTI vaccine on specific patient groups, overall this 343	  
represents a small target population and a limited market. A UTI vaccine would not be inserted into 344	  
national immunization schedules and thus would most likely only attract a private market, far away 345	  
from the revenues of a blockbuster vaccine. One possible way to circumvent this roadblock would 346	  
be the design of a universal E. coli vaccine that targets common surface proteins from both 347	  
extraintestinal and intestinal E. coli pathotypes. Such a vaccine would impact on multiple human 348	  
diseases, including extraintestinal infections such as urinary tract infection, meningitis and sepsis, 349	  
as well as severe intestinal diseases caused by enterotoxigenic, enterohaemorragic, 350	  
enteropathogenic, enteroinvasive, enteroaggregative and diffusely adherent E. coli pathotypes.  351	  
 352	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Table 1 - Analysis of the current pipeline (up to 5 years) for companies investing in E. coli vaccines 674	  
 675	  
Company Stage Description/Comments 
   
Sequoia Sciences PC Vaccine consisting of E. coli adhesins in development for the prevention of chronic 
UTI. Objective to enter clinical trials in 2013 after the optimization of adjuvants and 
vaccination protocols. Exclusive license to US Patent 6,500,434 obtained from 
Washington University in Saint Louis. 
   
GlycoVaxyn PC Conjugate vaccine against UPEC based on proprietary bioconjugate platform that 
enables the in vivo synthesis of polysaccharide-protein complexes.  
 
NanoBio PC Vaccine targeting UPEC surface antigens. Objective to develop an intranasally 
delivered vaccine using proprietary nanoemulsion adjuvant technology. Licencing 
agreement announced in 2011 in partnership with the University of Michigan. 
 
PC - preclinical.  676	  
 677	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Figure 1 - Schematic diagram of the major cell-surface associated or secreted virulence factors of 679	  
UPEC that contribute to colonization of the urinary tract. Fimbrial and non-fimbrial adhesins 680	  
mediate attachment to host epithelial cells. Flagella mediate motility and chemotaxis and contribute 681	  
to UPEC dissemination. Iron receptors facilitate the uptake of iron by UPEC. Secreted toxins 682	  
induce host cell lysis and disrupt host inflammatory signaling cascades. Outer membrane (OM) 683	  
proteins and lipoproteins are integral components of the UPEC outer membrane. Capsule and O-684	  
antigen promote host evasion and contribute to survival in the bloodstream. 685	  
 686	  
 687	  
 688	  
